Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET.

Sanchita RaychaudhuriChristine AbriaZachary T HarmanyCharles M SmithSmriti Kundu-RaychaudhuriSiba P RaychaudhuriAbhijit J Chaudhari

Published in: International journal of rheumatic diseases (2019)

18 F-FDG PET can detect changes in inflammatory activity occurring in response to the JAK inhibitor tofacitinib: (a) during peak and trough plasma drug levels, that is within mere hours of treatment; and (b) over a span of days.

Keyphrases

pet ct
positron emission tomography
pet imaging
rheumatoid arthritis
computed tomography
oxidative stress
combination therapy
adverse drug
replacement therapy